ZSTK

ZeroStack is not really an operating business you can underwrite — it's a shrinking, razor-thin pharmaceutical distributor (Phatebo, revenue concentrated in Germany) that management has re-cast as 'the first and largest decentralized AI treasury company' investing in 0G Tokens, Solana, Ethereum, Sui and Ripple. The distribution business itself is going backwards: revenue fell from $76.1M in FY2023 to $35.9M in FY2024 to $35.7M in FY2025, and at a 4.6% gross margin ($1.65M of gross profit on $35.7M of sales) it throws off almost nothing to cover corporate costs. Operating income was -$155M and net income -$120M — losses many multiples of revenue — driven by charges well beyond the distribution P&L, i.e. the crypto/AI-treasury overlay, not a business that is scaling toward profit.

The balance sheet looks superficially healthier (equity up to $70.6M, assets up ~397% to $130M), but that swing came from PIPE placements settled largely in 0G Tokens and a convertible note denominated in 95,333 Solana — so a large slice of 'equity' is volatile crypto marked at a point in time, not durable cash. Actual cash is just $5.6M against $50.8M of long-term debt, a $2.72M current debt slug, and -$8.68M of operating cash flow. That is a burn-and-dilute setup: the May 2025 shares were sold at $11.70 and the September PIPE units at $25.19, yet the stock now trades at $3.35 — holders who funded this are deep underwater, and further capital raises would dilute again from an already-tiny 2.43M share count.